The global market for long-read full-length complementary deoxyribonucleic acid (cDNA) sequencing is poised for significant growth, driven by advancements in sequencing technologies and the expanding field of genomics research. According to a report added to ResearchAndMarkets.com’s offerings, the market is expected to grow from $1.34 billion in 2025 to $1.59 billion in 2026, marking a compound annual growth rate (CAGR) of 18.6%1. This growth trajectory is anticipated to continue, with projections estimating the market will reach $3.18 billion by 2030, supported by a CAGR of 18.9%2.
Key factors contributing to this expansion include the rising demand for precision medicine, the integration of artificial intelligence in bioinformatics, and the increasing application of sequencing in rare disease research. Additionally, the development of cost-effective long-read sequencing workflows and the growing use of sequencing for alternative splicing detection are significant drivers. The market is also witnessing a surge in single-cell full-length cDNA sequencing adoption, which is crucial for high-fidelity platforms and transcript isoform characterization.
Precision medicine, which focuses on tailoring medical treatment to the individual characteristics of each patient, is a major catalyst for market growth. The need for detailed molecular information to guide therapeutic decisions is increasing, particularly for heterogeneous and therapy-resistant diseases. Long-read full-length cDNA sequencing provides crucial insights into transcript isoforms and biomarkers, aiding researchers and clinicians in selecting targeted therapies3.
The regulatory landscape reflects the momentum in personalized treatment development. In 2023, the U.S. Food and Drug Administration approved 16 new personalized therapies for rare diseases, a notable increase from six approvals in 2022. This trend underscores the growing role of genomics and transcriptomics in drug development and biomarker discovery.
Technology providers are responding to these demands by enhancing sequencing platforms and workflows. For instance, Pacific Biosciences of California launched the Kinnex RNA kits in December 2023. These kits are designed to advance long-read RNA research by offering ultra-long reads, high consensus accuracy, and compatibility with complex RNA samples. Such advancements facilitate the identification of alternative splicing events and previously undiscovered isoforms, thereby broadening applications across genomics and therapeutic target identification4.
Strategic collaborations are also playing a pivotal role in expanding capabilities in long-read single-cell transcriptomics. In February 2026, ArgenTag partnered with Pacific Biosciences to combine accurate long-read sequencing with single-cell analysis methods. This partnership aims to enhance cellular transcriptome profiling and improve the understanding of complex biological mechanisms5.
Regionally, North America led the market in 2025, benefiting from established genomics infrastructure and significant research investments. However, the Asia-Pacific region is expected to experience the fastest growth during the forecast period. The market’s geographical reach includes regions such as Southeast Asia, Western and Eastern Europe, North and South America, the Middle East, and Africa, with countries like the United States, China, and Germany being key players.
The market is segmented by technology, product type, sample type, application, and end-users. Technologies include Pacific Biosciences Single-Molecule Real-Time (PacBio SMRT) and Oxford Nanopore, among others. Product types range from instruments and sequencing platforms to data analysis software. Applications cover transcriptome analysis and gene expression studies, while end-users include academic institutions, pharmaceutical companies, and clinical laboratories.
Overall, the long-read full-length cDNA sequencing market is set for robust growth, driven by technological advancements and the increasing importance of precision medicine. As the market evolves, it presents numerous opportunities for technology developers, clinical laboratories, and biotechnology firms to innovate and expand their offerings.
Footnotes:
- The market is projected to grow from $1.34 billion in 2025 to $1.59 billion in 2026, with a CAGR of 18.6%. Source.
- The market is forecast to reach $3.18 billion by 2030, growing at a CAGR of 18.9%. Source.
- Precision medicine is a major driver of market growth, requiring detailed molecular information for therapeutic decisions. Source.
- Pacific Biosciences introduced Kinnex RNA kits to advance long-read RNA research in December 2023. Source.
- ArgenTag’s partnership with Pacific Biosciences aims to enhance single-cell transcriptomics capabilities. Source.
Featured Image: Megapixl @ Leowolfert
